Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
BeOne Medicines Ltd.
ISIN US07725L1026
|WKN A1437N
Market cap (in EUR)
38,132 m
Country
Switzerland
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Switzerland
Financials
Key metrics
| Market capitalisation, EUR | 38,132 m |
| EPS, EUR | 0.47 |
| P/B ratio | 8.6 |
| P/E ratio | 616.3 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 3,524 m |
| Net income, EUR | -596 m |
| Profit margin | -16.92% |
What ETF is BeOne Medicines Ltd. in?
There is 1 ETF which contains BeOne Medicines Ltd..
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.89% | Equity United States Health Care Biotech | 46 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.